These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22091418)

  • 21. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.
    Kloth JN; Oosting J; van Wezel T; Szuhai K; Knijnenburg J; Gorter A; Kenter GG; Fleuren GJ; Jordanova ES
    BMC Genomics; 2007 Feb; 8():53. PubMed ID: 17311676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
    Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
    Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reverse phase protein arrays in signaling pathways: a data integration perspective.
    Creighton CJ; Huang S
    Drug Des Devel Ther; 2015; 9():3519-27. PubMed ID: 26185419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Screening Platforms and RPPA.
    Dawson JC; Warchal SJ; Carragher NO
    Adv Exp Med Biol; 2019; 1188():203-226. PubMed ID: 31820390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating genomics in head and neck cancer treatment: Promises and pitfalls.
    Thariat J; Vignot S; Lapierre A; Falk AT; Guigay J; Van Obberghen-Schilling E; Milano G
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):397-406. PubMed ID: 25979769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
    Baty F; Joerger M; Früh M; Klingbiel D; Zappa F; Brutsche M
    J Transl Med; 2017 Mar; 15(1):66. PubMed ID: 28359318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
    Xu T; Su B; Huang P; Wei W; Deng Y; Sehgal V; Wang D; Jiang J; Zhang G; Li A; Yang H; Claret FX
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 27883284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
    Psyrri A; Seiwert TY; Jimeno A
    Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
    Ganesh SK; Skelding KA; Mehta L; O'Neill K; Joo J; Zheng G; Goldstein J; Simari R; Billings E; Geller NL; Holmes D; O'Neill WW; Nabel EG
    Pharmacogenomics; 2004 Oct; 5(7):952-1004. PubMed ID: 15469413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.
    Vici P; Pizzuti L; Mariani L; Zampa G; Santini D; Di Lauro L; Gamucci T; Natoli C; Marchetti P; Barba M; Maugeri-Saccà M; Sergi D; Tomao F; Vizza E; Di Filippo S; Paolini F; Curzio G; Corrado G; Michelotti A; Sanguineti G; Giordano A; De Maria R; Venuti A
    Expert Rev Vaccines; 2016 Oct; 15(10):1327-36. PubMed ID: 27063030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
    Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
    J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers.
    Yoshinouchi M; Hongo A; Nakamura K; Kodama J; Itoh S; Sakai H; Kudo T
    J Clin Microbiol; 1999 Nov; 37(11):3514-7. PubMed ID: 10523544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over Expressed TKTL1, CIP-2A, and B-MYB Proteins in Uterine Cervix Epithelium Scrapings as Potential Risk Predictive Biomarkers in HR-HPV-Infected LSIL/ASCUS Patients.
    Chiarini A; Liu D; Rassu M; Armato U; Eccher C; Dal Prà I
    Front Oncol; 2019; 9():213. PubMed ID: 31001477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.
    Mullokandov MR; Kholodilov NG; Atkin NB; Burk RD; Johnson AB; Klinger HP
    Cancer Res; 1996 Jan; 56(1):197-205. PubMed ID: 8548763
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.